LSL Pharma Group Balance Sheet Health
Financial Health criteria checks 4/6
LSL Pharma Group has a total shareholder equity of CA$19.5M and total debt of CA$11.2M, which brings its debt-to-equity ratio to 57.4%. Its total assets and total liabilities are CA$37.0M and CA$17.5M respectively.
Key information
57.4%
Debt to equity ratio
CA$11.17m
Debt
| Interest coverage ratio | n/a |
| Cash | CA$289.00k |
| Equity | CA$19.47m |
| Total liabilities | CA$17.48m |
| Total assets | CA$36.95m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: LSL's short term assets (CA$9.9M) exceed its short term liabilities (CA$9.3M).
Long Term Liabilities: LSL's short term assets (CA$9.9M) exceed its long term liabilities (CA$8.2M).
Debt to Equity History and Analysis
Debt Level: LSL's net debt to equity ratio (55.9%) is considered high.
Reducing Debt: Insufficient data to determine if LSL's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LSL has sufficient cash runway for 1 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: LSL is forecast to have sufficient cash runway for 0 months based on free cash flow estimates, but has since raised additional capital.